GPT2 mediates glutamine metabolism-driven metabolic alterations in platinum-resistant ovarian cancer cells

Area of Science:

• Oncology
• Cancer Metabolism
• Drug Resistance

Background:

• Metabolic reprogramming is a hallmark of cancer, contributing to drug resistance, particularly in ovarian cancer.
• Platinum resistance significantly impacts survival rates in ovarian cancer patients.
• The specific metabolic mechanisms underlying platinum resistance in ovarian cancer remain unclear.

Purpose of the Study:

• To investigate metabolic differences between platinum-resistant and platinum-sensitive ovarian cancer cells.
• To identify key metabolic enzymes and pathways involved in chemoresistance.
• To evaluate glutamic-pyruvic transaminase 2 (GPT2) as a potential therapeutic target.

Main Methods:

• Comparative analysis of metabolic signatures in platinum-resistant versus sensitive ovarian cancer cell lines.
• Quantification of oxidative phosphorylation (OXPHOS), glutaminolysis, and tricarboxylic acid (TCA) cycle metabolites.
• Assessment of key enzyme expression, including GPT2.
• GPT2 gene knockout in chemoresistant cells to determine its functional role.

Main Results:

• Chemoresistant ovarian cancer cells exhibit increased OXPHOS, glutaminolysis, and TCA cycle activity.
• Upregulation of GPT2, a key glutaminolysis enzyme, was observed in chemoresistant cells.
• High GPT2 gene expression correlates with poorer prognosis in ovarian cancer patients.
• GPT2 knockout reversed the metabolic phenotype and restored sensitivity to platinum drugs.

Conclusions:

• GPT2 is a critical mediator linking glutaminolysis, the TCA cycle, and OXPHOS in chemoresistant ovarian cancer.
• GPT2 represents a promising therapeutic target to overcome platinum resistance.
• Targeting GPT2 could potentially re-sensitize ovarian cancer to chemotherapy.